#1Pending#2Contents OO HEALTHCARE CELLTRION Section 01. 2Q23 Business Results Section 02. Key Products Appendix#32Q23 Business Results Key Products Appendix Revenue: Increased both QoQ and YoY due to stable prescription of highly profitable products such as Remsima®, RemsimaⓇSC and YuflymaⓇ Operating Profit: Cost increased by expansion of the direct sales and sales operations resulted in lower OP although the revenue was increased by the sales of high-margin products Net Profit: Inventory of subsidiary in Hungary purchased from the headquarter resulted in unrealized gain which increased the income tax rate, and NP decreased in a consequence 2Q23 Business Results (KRW bn) '22.2Q '23.1Q '23.2Q % YoY %QoQ Revenue 519.0 503.6 525.8 1.3% 4.4% Gross Profit 140.9 153.2 150.9 7.1% -1.5% (%) 27.1% 30.4% 28.7% 1.6%p -1.7%p SG&A 66.8 102.2 116.8 74.9% 14.3% (%) 12.9% 20.3% 22.2% 9.3%p 1.9%p Personnel expenses 13.7 18.1 19.7 43.8% 8.8% Research expenses 0.8 4.6 9.4 1,075.0% 104.3% Advertising expenses 6.6 10.2 15.5 134.8% 52.0% Commissions 24.3 30.1 37.8 55.6% 25.6% Transportation expenses 7.8 13.9 11.3 44.9% -18.7% Operating Profit 74.1 51.0 34.1 -54.0% -33.1% (%) 14.3% 10.1% 6.5% -7.8%p -3.6%p EBIT 95.2 120.1 32.1 -66.3% -73.3% Net Profit 39.1 54.1 17.4 -55.5% -67.8% Investor Relations 2023 3#4Pending#5Pending#6Pending#7Pending#8Pending#9Pending#10Pending#11VegzelmaⓇ ✓ In Europe, actively participated in the tender based on its price advantage and the synergy with existing oncology products ✓ Launched in April 2023, it has registered with Medicare and is currently in the process of discussion to be listed on the plans The global market size of Bevacizumab 41% 24% Global Bevacizumab Market Size $5.7bn 24% 11% US ■ Europe ■ Japan ROW Note: Market size is as of 2022 Source: IQVIA Europe US Launched in October 2022 Obtained the tender with price and the portfolio advantages - Received orders from Finland, Italy, and Belgium - More participation in a tender of other EU countries Launched in April 2023 - Listed in Medicare which covers 20% of the population - Negotiating with the number of payers to be registered in the list Investor Relations 2023 11 2Q23 Business Results Key Products Appendix#12Pending#13Pending#14Pending#15Pending